Hodgkin Lymphoma
Richard T. Hoppe(Stanford Medicine), Joachim Yahalom(Unknown), Bouthaina S. Dabaja, Leo I. Gordon(Northwestern University), Barbara Pro(The University of Texas MD Anderson Cancer Center), David G. Maloney(Fred Hutch Cancer Center), Monika L. Metzger(St. Jude Children's Research Hospital), Matthew M. Poppe(University of Utah), Peter Mauch(Western Sydney University), David B. Mansur(University Hospitals Cleveland Medical Center), Ysabel Durón(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ephraim P. Hochberg(Massachusetts General Hospital), Weiyun Z. Ai(City College of San Francisco), Kristie A. Blum(Emory University), Ranjana H. Advani(Stanford Medicine), David Morgan(Vanderbilt University Medical Center), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center), Richard F. Ambinder(Johns Hopkins University), Andres Forero, Joseph O. Moore(Cancer Institute (WIA)), Philip J. Bierman(Susan Thompson Buffett Foundation), Celeste Bello(Moffitt Cancer Center), Craig H. Moskowitz(University of Miami), Lawrence M. Weiss(NeoGenomics (United States)), Jane N. Winter(Northwestern University)
Cited by 40
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k